Group items matching

in title, tags, annotations or url

NHS England's decision to forgo commissioning puberty suppressing hormones (PSH) for children and young people, citing insufficient evidence of their safety and clinical effectiveness, follows a comprehensive review conducted by the National Institute for Health and Care Excellence (NICE) in 2020. The clinical report underscores that "PSH treatment options will not be part of routine commissioning" for people under the age of 18 in England grappling with gender incongruence or dysphoria. The NHS England review analysed nine observational studies on Gonadotrophin Releasing Hormone Analogues (GnRHa) and found no statistically significant difference in gender dysphoria, mental health, body image, and psychosocial functioning among children and adolescents treated with GnRHa. Duncan Rudkin, chief executive of the General Pharmaceutical Council (GPhC), acknowledged the challenges faced by pharmacy professionals regarding prescriptions for puberty suppressing hormones, stating:

The Council of Pharmaceutical Society NI (PSNI) has introduced an 8-week public consultation on proposed Guidance on Pharmacy Staffing Levels within registered premises. The principle-based Guidance seeks to assist Pharmacy Owners and Superintendents to ensure that each pharmacy has enough appropriately skilled and qualified staff to provide safe and effective pharmacy services to the public. All registered pharmacies will have to meet the standards set out in the Premises Standards, when commenced. PSNI said: "The proposed Guidance should also help ensure a working environment that will facilitate pharmacists to meet their professional obligations under the Professional Standards of Conduct, Ethics and Performance for Pharmacists in Northern Ireland (2016)." "Whilst other health regulators have primary responsibility for systems regulation outside of regulated premises, we consider that the principles outlined in this Guidance, will be helpful for managers working with pharmacy teams in different settings."

Pharmacists working in Northern Ireland think the retention fees are too high, and most would prefer to pay in instalments, if that option is available, amid the increased living costs, a new survey has found. 97 per cent of the respondents to the survey, conducted by the Pharmacists' Defence Association (PDA) of its Northern Irish members, felt the fees were too high. Four in five said they would opt to pay in instalments if this option were available to them in light of the challenges of significant one-off payments. On average, the fees accounted for 23 per cent of a pharmacist's take-home pay for one month, and 98 per cent did not see any value added to their professional standing for the sum, according to the survey. The PDA said the respondents also reported feeling disadvantaged among their colleagues in terms of how fees are collected, with many also wondering why the registration fee was not offset for those on maternity leave or working reduced or flexible hours.